Stocklytics Platform
Asset logo for symbol TGTX
TG Therapeutics
TGTX87
$29.54arrow_drop_down4.29%-$1.32
High Quality
High Growth
Asset logo for symbol TGTX
TGTX87

$29.54

arrow_drop_down4.29%

Performance History

Chart placeholder
Key Stats
Open$31.06
Prev. Close$30.84
EPS-0.11
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range30.33
31.13
52 Week Range6.46
36.37
Ratios
EPS-0.11

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About TG Therapeutics (TGTX)

TG Therapeutics Inc (TGTX) is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments for B-cell malignancies and autoimmune diseases. The company's primary focus is on the development of novel antibody-based therapies that target key proteins involved in these diseases. TGTX is headquartered in New York City and has a robust pipeline of drug candidates that are at various stages of development.
One of TG Therapeutics' lead drug candidates is umbralisib, a selective inhibitor of PI3K-delta and CK1-epsilon. This drug has shown promising results in clinical trials for the treatment of various hematologic malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). In fact, umbralisib has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael S. Weiss Esq.
Headquarters
Morrisville
Employees
237
Exchange
NASDAQ
add TG Therapeutics to watchlist

Keep an eye on TG Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is TG Therapeutics 's (TGTX) price per share?

The current price per share for TG Therapeutics (TGTX) is $29.54. The stock has seen a price change of -$1.32 recently, indicating a -4.3% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for TG Therapeutics (TGTX)?

For TG Therapeutics (TGTX), the 52-week high is $36.37, which is 23.13% from the current price. The 52-week low is $6.46, the current price is 357.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is TG Therapeutics (TGTX) a growth stock?

TG Therapeutics (TGTX) has shown an average price growth of -4.94% over the past three years. It has received a score of 86 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying TG Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is TG Therapeutics (TGTX) stock price performance year to date (YTD)?

As of the latest data, TG Therapeutics (TGTX) has a year-to-date price change of 73.36%. Over the past month, the stock has experienced a price change of 29.39%. Over the last three months, the change has been 41.61%. Over the past six months, the figure is 64.48%. Looking at a longer horizon, the five-year price change stands at 270.41%.
help

Is TG Therapeutics (TGTX) a profitable company?

TG Therapeutics (TGTX) has a net income of $12.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.77% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 14.82% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $233.66M, although specific revenue growth data is currently not available. The gross profit is $219.11M. Operating income is noted at $20.63M. Furthermore, the EBITDA is $26.1M.
help

What is the market capitalization of TG Therapeutics (TGTX)?

TG Therapeutics (TGTX) has a market capitalization of $4.6B. The average daily trading volume is 29.54, indicating the stock's liquidity and investor engagement.

News

"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
INVESTING
Jun 27, 2024

"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
CALENDAR OF EVENTS
Jun 7, 2024

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
CALENDAR OF EVENTS
HEALTH
Jun 3, 2024

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
HEALTH
CLINICAL STUDY
May 31, 2024

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
COMPANY ANNOUNCEMENT
May 28, 2024

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

Wall Street Breakfast: The Week Ahead
May 12, 2024

Wall Street Breakfast: The Week Ahead

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level